DANYELZA (naxitamab-gqgk) for the Treatment of Neuroblastoma

Image 1-DANYELZA (naxitamab-gqgk)
DANYELZA (naxitamab-gqgk) is the first and only FDA-approved humanised immunotherapy indicated for the treatment of high-risk neuroblastoma (HR-NB). Credit: Y-mAbs Therapeutics, Inc.